|
Improvement in PAP in patients with sarcoidosis-associated pulmonary hypertension following bosentan treatment |
||||
| Patient |
Initial mean PAP (mmHg) |
Follow-up mean PAP (mmHg) |
Pulmonary hypertension therapy |
Other sarcoidosis medications |
|
|
||||
| 1 |
73 |
41 |
Epoprostenol |
Prednisone, methotrexate, azathioprine, infliximab |
| 2a |
63 |
45 |
Bosentan |
Prednisone |
| 3a |
61 |
ND |
Bosentan, epoprostenol |
Prednisone, azathioprine |
| 4 |
53 |
23 |
Amlodipine |
Prednisone, methotrexate |
| 5 |
50 |
ND |
Bosentan |
Prednisone, methotrexate |
| 6 |
38 |
36 |
Bosentan |
Prednisone, methotrexate, azathioprine |
| 7 |
36 |
24 |
Bosentan |
Prednisone, methotrexate, infliximab |
|
Shown are data demonstrating improvement in pulmonary artery pressure (PAP) following addition of bosentan to standard anti-inflammatory therapy in a small cohort of patients with sarcoidosis-associated pulmonary hypertension. aPatient died. ND, not determined. | ||||
Baughman Arthritis Research & Therapy 2007 9(Suppl 2):S8 doi:10.1186/ar2192 |
||||